Characterization of the La Crosse Virus glycoprotein fusion peptide

拉克罗斯病毒糖蛋白融合肽的表征

基本信息

  • 批准号:
    7526148
  • 负责人:
  • 金额:
    $ 34.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-01 至 2013-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): La Crosse virus (LACV), a NIAID Category B priority pathogen, is a common cause of pediatric encephalitis and aseptic meningitis in areas of the Midwestern United States where its principal mosquito vector, Ochlerotatus (formerly Aedes) trisariatus, resides. The structural components of the LACV genome (L, M, and S) have essential, well- defined roles in virus pathogenesis. Previous studies from our laboratory using wild-type LACV and TAHV 181/57, a highly neurovirulent strain with low neuroinvasiveness, have mapped the neuroinvasive phenotype to the M segment, which encodes Gn, Gc, and a non-structural protein, NSm. More recently, using recombinant glycoproteins we demonstrated that the region corresponding to the membrane proximal two-thirds of Gc, amino acids 860-1442, is critical in mediating fusion and cell entry. Further computational analysis identified structural similarities between LACV Gc amino acid region 970-1350 and the E1 fusion protein of two alphaviruses: Sindbis virus and Semliki Forrest virus (SFV). Collectively, these studies suggested that the LACV Gc, like the alphavirus E1 and the flavivirus E, functions as a type II fusion protein. Within Gc there is a 22 amino acid hydrophobic segment, 1066-1087, that is predicted to correlate structurally with a hydrophobic domain of SFV and Sindbis virus E1. The short sequence is highly conserved within the family Bunyaviridae and features several conserved cysteine residues, as do other type II proteins, such as SFV E1. Based on these features, and in our mutagenesis studies, our working hypothesis is that the LACV Gc (1066-1087) functions as its fusion peptide. In the first specific aim, we will extend these studies by analyzing fusion in mosquito cells, and by identifying peptides and antibodies that further associate this region with fusion and entry. In the second specific aim, we will use a newly developed reverse genetics system to construct LACV mutants incorporating the knowledge gained from the studies on the isolated glycoproteins. These viruses will then allow us to extend our in vitro findings to a mouse model of LACV encephalitis previously developed by our group (third specific aim). Importantly, as this hydrophobic region is highly conserved among the Bunyaviridae, this proposal will also elucidate mechanisms of virus fusion and entry among other emerging bunyaviruses including the NIAID Category A and C pathogens CCHFV and RVFV and will have significant implications for anti-viral therapy. PUBLIC HEALTH RELEVANCE La Crosse Virus is a common cause of pediatric encephalitis and aseptic meningitis in the Midwestern United States where it principal mosquito vector, Ochlerotatus triseriatus resides. We have identified the fusion peptide for the La Crosse virus glycoprotein Gc. The studies outlined in this proposal will define mechanisms of fusion and entry for La Crosse Virus in both the mammalian and insect host, determine the role of the newly identified fusion domain in the neuropathogenesis of LACV encephalitis, and develop anti-viral therapies (fusion peptide inhibitors and attenuated virus vaccines).
描述(由申请方提供):拉克罗斯病毒(LACV)是一种NIAID B类优先病原体,是其主要蚊媒Ochlerotatus(原Aedes)trisariatus所在的美国中西部地区儿童脑炎和无菌性脑膜炎的常见病因。LACV基因组的结构组分(L、M和S)在病毒发病机制中具有基本的、明确的作用。我们实验室以前使用野生型LACV和TAHV 181/57(一种具有低神经侵袭性的高神经毒性毒株)的研究已经将神经侵袭表型映射到M片段,该片段编码Gn,Gc和非结构蛋白NSm。最近,使用重组糖蛋白,我们证明了对应于膜近端Gc的三分之二的区域,氨基酸860-1442,在介导融合和细胞进入中是至关重要的。进一步的计算分析鉴定了LACV Gc氨基酸区970-1350与两种甲病毒(辛德毕斯病毒和塞姆利基福雷斯特病毒(SFV))的E1融合蛋白之间的结构相似性。总的来说,这些研究表明LACV Gc与甲病毒E1和黄病毒E一样,具有II型融合蛋白的功能。在Gc内,存在22个氨基酸的疏水区段1066-1087,其被预测为与SFV和辛德毕斯病毒E1的疏水结构域结构相关。短序列在布尼亚病毒科中高度保守,并具有几个保守的半胱氨酸残基,其他II型蛋白如SFV E1也是如此。基于这些特征,并且在我们的诱变研究中,我们的工作假设是LACV Gc(1066-1087)作为其融合肽起作用。在第一个具体目标中,我们将通过分析蚊子细胞中的融合来扩展这些研究,并通过鉴定进一步将该区域与融合和进入相关联的肽和抗体。在第二个具体的目标,我们将使用一个新开发的反向遗传学系统,构建LACV突变体纳入从分离的糖蛋白的研究中获得的知识。这些病毒将使我们能够将我们的体外发现扩展到我们小组先前开发的LACV脑炎小鼠模型(第三个具体目标)。重要的是,由于该疏水区域在布尼亚病毒科中高度保守,因此该提议还将阐明其他新兴布尼亚病毒(包括NIAID A类和C类病原体CCHFV和RVFV)之间的病毒融合和进入机制,并将对抗病毒治疗具有重要意义。公共卫生相关性拉克罗斯病毒是美国中西部地区儿童脑炎和无菌性脑膜炎的常见病因,其主要蚊媒三列黄蚊(Ochlerotatus triseriatus)居住在该地区。我们鉴定了拉克罗斯病毒糖蛋白Gc的融合肽。本提案中概述的研究将确定拉克罗斯病毒在哺乳动物和昆虫宿主中的融合和进入机制,确定新鉴定的融合结构域在LACV脑炎神经发病机制中的作用,并开发抗病毒疗法(融合肽抑制剂和减毒病毒疫苗)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Francisco Gonzalez-Scarano其他文献

Francisco Gonzalez-Scarano的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Francisco Gonzalez-Scarano', 18)}}的其他基金

Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
  • 批准号:
    7880387
  • 财政年份:
    2009
  • 资助金额:
    $ 34.78万
  • 项目类别:
Research Training Program in Disease-Oriented Neuroscience
面向疾病的神经科学研究培训计划
  • 批准号:
    8037252
  • 财政年份:
    2009
  • 资助金额:
    $ 34.78万
  • 项目类别:
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
  • 批准号:
    7624319
  • 财政年份:
    2008
  • 资助金额:
    $ 34.78万
  • 项目类别:
Characterization of the La Crosse Virus glycoprotein fusion peptide
拉克罗斯病毒糖蛋白融合肽的表征
  • 批准号:
    7878107
  • 财政年份:
    2008
  • 资助金额:
    $ 34.78万
  • 项目类别:
Core--Developmental Facility
核心--开发设施
  • 批准号:
    7456542
  • 财政年份:
    2007
  • 资助金额:
    $ 34.78万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7016245
  • 财政年份:
    2005
  • 资助金额:
    $ 34.78万
  • 项目类别:
Interactions Between HIV Gag and Exosomal Proteins
HIV Gag 和外泌体蛋白之间的相互作用
  • 批准号:
    7016241
  • 财政年份:
    2005
  • 资助金额:
    $ 34.78万
  • 项目类别:
Core--Developmental Facility
核心--开发设施
  • 批准号:
    6801288
  • 财政年份:
    2004
  • 资助金额:
    $ 34.78万
  • 项目类别:
SELECTION OF CD4-INDEPENDENT GP120 VARIANTS AND PROGRESSION TO AIDS
不依赖 CD4 的 GP120 变体的选择和进展为艾滋病
  • 批准号:
    6939803
  • 财政年份:
    2003
  • 资助金额:
    $ 34.78万
  • 项目类别:
Genetics of Simian Immunodeficiency Virus Encephalopathy
猿猴免疫缺陷病毒脑病的遗传学
  • 批准号:
    6682733
  • 财政年份:
    2002
  • 资助金额:
    $ 34.78万
  • 项目类别:

相似海外基金

Multi-component interventions to reducing unhealthy diets and physical inactivity among adolescents and youth in sub-Saharan Africa (Generation H)
采取多方干预措施减少撒哈拉以南非洲青少年的不健康饮食和缺乏身体活动(H 代)
  • 批准号:
    10106976
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    EU-Funded
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Fellowship
Decolonization, Appropriation and the Materials of Literature in Africa and its Diaspora
非洲及其侨民的非殖民化、挪用和文学材料
  • 批准号:
    EP/Y024516/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
Exploring "Actionable Information" for Learning Improvement in Rural East Africa: A Positive Deviance Approach
探索东非农村地区学习改进的“可行信息”:积极偏差方法
  • 批准号:
    24K00390
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Water stressed cities: individual choice, access to water and pathways to resilience in sub-Saharan Africa
缺水城市:撒哈拉以南非洲地区的个人选择、水资源获取和恢复力途径
  • 批准号:
    MR/X022943/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Fellowship
Protecting Women from Economic shocks to fight HIV in Africa (POWER)
保护非洲妇女免受经济冲击,抗击艾滋病毒 (POWER)
  • 批准号:
    MR/Y003837/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Fellowship
Tackling antimicrobial resistance across dentistry in Sub-Saharan Africa.
解决撒哈拉以南非洲牙科领域的抗菌素耐药性问题。
  • 批准号:
    MR/Y019695/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
ePowerCart - Affordable Mobile Clean Energy for Remote Communities in Rural Sub-Saharan Africa and India
ePowerCart - 为撒哈拉以南非洲和印度农村偏远社区提供经济实惠的移动清洁能源
  • 批准号:
    10076185
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Collaborative R&D
Co-designing effective Nature-based Solutions in coastal West Africa
在西非沿海共同设计有效的基于自然的解决方案
  • 批准号:
    NE/Z503460/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Research Grant
NIGHTCOOL: Deployment of FREECOOL+ for night cooling strategies in Africa
NIGHTCOOL:部署 FREECOOL 以实施非洲夜间制冷策略
  • 批准号:
    10105520
  • 财政年份:
    2024
  • 资助金额:
    $ 34.78万
  • 项目类别:
    Demonstrator
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了